Edwards Lifesciences Corp
EW- Exchange
- NYSE
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- SEC CIK
- 0001099800
In the last 90 days, Edwards Lifesciences Corp insiders filed 0 open-market purchases and 9 sales; 1,348 institutions reported holding it in 13F filings for Q2 2026, worth $47.2B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:11 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 10, 2026 | Feb 11, 2025 | Feb 6, 2024 | Jan 31, 2023 | Jan 26, 2022 |
| Revenue | $6.07B | $5.44B | $6.00B | $5.38B | $5.23B |
| Cost of revenue | $1.33B | $1.12B | $1.38B | $1.08B | $1.25B |
| Gross profit | $4.73B | $4.32B | $4.63B | $4.30B | $3.98B |
| Research and development | $1.08B | $1.05B | $1.07B | $945.2M | $903.1M |
| Selling, general and administrative | $2.09B | $1.79B | $1.82B | $1.57B | $1.49B |
| Operating income | $1.26B | $1.38B | $1.53B | $1.75B | $1.69B |
| Interest expense | – | – | $17.6M | $19.2M | $18.4M |
| Income tax | $216.9M | $152.1M | $198.7M | $245.5M | $198.9M |
| Net income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B |
| EPS, basic | $1.84 | $6.98 | $2.31 | $2.46 | $2.41 |
| EPS, diluted | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 |
| Weighted shares, basic | 584.8M | 597.7M | 606.7M | 619.0M | 623.3M |
| Weighted shares, diluted | 585.8M | 599.3M | 609.4M | 624.2M | 631.2M |
| Margins and growth | |||||
| Gross margin | 78.0% | 79.5% | 77.0% | 79.9% | 76.1% |
| Operating margin | 20.8% | 25.3% | 25.5% | 32.5% | 32.3% |
| Net margin | 17.7% | 76.7% | 23.4% | 28.3% | 28.7% |
| Revenue growth, year over year | +11.5% | −9.4% | +11.6% | +2.9% | +19.3% |
| Net income growth, year over year | −74.3% | +197.7% | −7.9% | +1.3% | +82.5% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 10, 2026 | Feb 11, 2025 | Feb 6, 2024 | Jan 31, 2023 | Jan 26, 2022 |
| Cash and equivalents | $2.94B | $3.05B | $1.14B | $769.0M | $862.8M |
| Short-term investments | $1.29B | $930.7M | $500.5M | $446.3M | $604.0M |
| Accounts receivable | $659.6M | $609.1M | $775.1M | $643.0M | $582.2M |
| Inventory | $1.13B | $1.09B | $1.17B | $875.5M | $726.7M |
| Total current assets | $6.74B | $6.29B | $4.04B | $3.10B | $3.18B |
| Property, plant and equipment | $1.81B | $1.69B | $1.75B | $1.63B | $1.55B |
| Goodwill | $1.77B | $1.78B | $1.25B | $1.16B | $1.17B |
| Intangible assets | $1.13B | $1.18B | $428.4M | $285.2M | $323.6M |
| Total assets | $13.7B | $13.1B | $9.36B | $8.29B | $8.50B |
| Accounts payable | $227.5M | $197.4M | $201.4M | $201.9M | $204.5M |
| Total current liabilities | $1.81B | $1.51B | $1.20B | $1.02B | $1.03B |
| Long-term debt | $598.3M | $597.7M | $597.0M | $596.3M | $595.7M |
| Total liabilities | $3.36B | $2.99B | $2.64B | $2.49B | $2.67B |
| Shareholders' equity | $10.3B | $10.1B | $6.72B | $5.81B | $5.84B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 10, 2026 | Feb 11, 2025 | Feb 6, 2024 | Jan 31, 2023 | Jan 26, 2022 |
| Operating cash flow | $1.60B | $542.3M | $895.8M | $1.22B | $1.73B |
| Capital expenditures | $260.2M | $252.4M | $253.0M | $244.6M | $325.8M |
| Free cash flow | $1.33B | $289.9M | $642.8M | $973.6M | $1.41B |
| Depreciation and amortization | $156.6M | $155.2M | $144.9M | $139.6M | $134.8M |
| Stock-based compensation | $158.1M | $162.3M | $139.4M | $126.8M | $109.3M |
| Share buybacks | $893.4M | $1.16B | $879.6M | $1.73B | $512.8M |
| Investing cash flow | -$712.9M | $2.31B | $173.8M | $252.3M | -$1.72B |
| Financing cash flow | -$956.8M | -$983.0M | -$711.0M | -$1.58B | -$356.3M |
| Net change in cash | -$119.3M | $1.91B | $375.4M | -$94.8M | -$332.8M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 2.6% | 3.0% | 2.3% | 2.4% | 2.1% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 31, 2026 | 575.0M | −0.9% | SEC |
| Jul 31, 2026 | 576.4M | −1.8% | SEC |
| Apr 30, 2026 | 575.8M | −1.8% | SEC |
| Jan 31, 2026 | 580.8M | −1.2% | SEC |
| Oct 31, 2025 | 580.3M | −1.6% | SEC |
| Jul 31, 2025 | 587.1M | −2.5% | SEC |
| Apr 30, 2025 | 586.6M | −2.7% | SEC |
| Jan 31, 2025 | 587.9M | −2.2% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.